Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera von QUINTAS-CARDAMA, Alfonso, KANTARJIAN, Hagop, VERSTOVSEK, Srdan, MANSHOURI, Taghi, LUTHRA, Rajyalakshmi, ESTROV, Zeev, PIERCE, Sherry, RICHIE, Mary Ann, BORTHAKUR, Gautam, KONOPLEVA, Marina, CORTES, Jorge

Volltext

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study von Bose, Prithviraj, Masarova, Lucia, Pemmaraju, Naveen, Bledsoe, Sharon D, Daver, Naval G, Jabbour, Elias J, Kadia, Tapan M, Estrov, Zeev, Kornblau, Steven M, Andreeff, Michael, Jain, Nitin, Cortes, Jorge E, Borthakur, Gautam, Alvarado, Yesid, Richie, Mary Ann, Dobbins, Mackenzie H, McCrackin, Selene A, Zhou, Lingsha, Pierce, Sherry A, Wang, Xuemei, Pike, Allison M, Garcia-Manero, Guillermo, Kantarjian, Hagop M, Verstovsek, Srdan

Volltext

P1025: A PILOT STUDY OF THE ANTI‐SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS von Bose, Prithviraj, Masarova, Lucia, Pemmaraju, Naveen, Dobbins, Mackenzie, Jain, Nitin, Abbas, Hussein, Kornblau, Steven, Maiti, Abhishek, Veletic, Ivo, Manshouri, Taghi, Bledsoe, Sharon, Ann Richie, Mary, Hall‐Moore, Nakiuda, Zhou, Lingsha, Wang, Xuemei, Kantarjian, Hagop, Estrov, Zeev, Verstovsek, Srdan

Volltext

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation von Ravandi, Farhad, Alattar, Mona Lisa, Grunwald, Michael R., Rudek, Michelle A., Rajkhowa, Trivikram, Richie, Mary Ann, Pierce, Sherry, Daver, Naval, Garcia-Manero, Guillermo, Faderl, Stefan, Nazha, Aziz, Konopleva, Marina, Borthakur, Gautam, Burger, Jan, Kadia, Tapan, Dellasala, Sara, Andreeff, Michael, Cortes, Jorge, Kantarjian, Hagop, Levis, Mark

Volltext

Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid Leukemia von Ohanian, Maro, Garcia‐Manero, Guillermo, Levis, Mark, Jabbour, Elias, Daver, Naval, Borthakur, Gautam, Kadia, Tapan, Pierce, Sherry, Burger, Jan, Richie, Mary Ann, Patel, Keyur, Andreeff, Michael, Estrov, Zeev, Cortes, Jorge, Kantarjian, Hagop, Ravandi, Farhad

Volltext

Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years von Masarova, Lucia, Bose, Prithviraj, Pemmaraju, Naveen, Richie, Mary Ann, Borthakur, Gautam, Estrov, Zeev E., Kantarjian, Hagop, Patel, Keyur P., Verstovsek, Srdan

Volltext

A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis von Bose, Prithviraj, Manshouri, Taghi, Bledsoe, Sharon D., Jain, Nitin, Masarova, Lucia, Pemmaraju, Naveen, Hall, Nakiuda, Richie, Mary Ann, Wang, Xuemei, Kantarjian, Hagop, Estrov, Zeev E., Verstovsek, Srdan

Volltext

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial von Short, Nicholas J, Kantarjian, Hagop M, Loghavi, Sanam, Huang, Xuelin, Qiao, Wei, Borthakur, Gautam, Kadia, Tapan M, Daver, Naval, Ohanian, Maro, Dinardo, Courtney D, Estrov, Zeev, Kanagal-Shamanna, Rashmi, Maiti, Abhishek, Benton, Christopher B, Bose, Prithviraj, Alvarado, Yesid, Jabbour, Elias, Kornblau, Steven M, Pemmaraju, Naveen, Jain, Nitin, Gasior, Yvonne, Richie, Mary Ann, Pierce, Sherry, Cortes, Jorge, Konopleva, Marina, Garcia-Manero, Guillermo, Ravandi, Farhad

Volltext

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia von Daver, Naval, Boumber, Yanis, Kantarjian, Hagop, Ravandi, Farhad, Cortes, Jorge, Rytting, Michael E, Kawedia, Jitesh D, Basnett, Jordan, Culotta, Kirk S, Zeng, Zhihong, Lu, Hongbo, Richie, Mary Ann, Garris, Rebecca, Xiao, Lianchun, Liu, Wenbin, Baggerly, Keith A, Jabbour, Elias, O'Brien, Susan, Burger, Jan, Bendall, Linda J, Thomas, Deborah, Konopleva, Marina

Volltext

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis von Bose, Prithviraj, Masarova, Lucia, Pemmaraju, Naveen, Bledsoe, Sharon D., Daver, Naval, Jabbour, Elias J., Kadia, Tapan M., Estrov, Zeev E., Kornblau, Steven M., Andreeff, Michael, Cortes, Jorge E., Jain, Nitin, Borthakur, Gautam, Alvarado, Yesid, Huynh-Lu, Julie, Nguyen-Cao, Madeleine M., Richie, Mary Ann, Dobbins, Mackenzie H., McCrackin, Selene Andrea, Zhou, Lingsha, Pierce, Sherry A., Wang, Xuemei, Pike, Allison M., Garcia-Manero, Guillermo, Kantarjian, Hagop, Verstovsek, Srdan

Volltext

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study von Bose, Prithviraj, Pemmaraju, Naveen, Masarova, Lucia, Bledsoe, Sharon D., Daver, Naval, Jabbour, Elias, Kadia, Tapan M., Estrov, Zeev E., Kornblau, Steven M., Andreeff, Michael, Cortes, Jorge E., Jain, Nitin, Borthakur, Gautam, Alvarado, Yesid, Huynh-Lu, Julie, Nguyen-Cao, Madeleine, Richie, Mary Ann, Dobbins, Mackenzie H., Zhou, Lingsha, Pierce, Sherry A., Wang, Xuemei, Pike, Allison M., Garcia-Manero, Guillermo, Kantarjian, Hagop M., Verstovsek, Srdan

Volltext

PEG-IFN-α-2b therapy in BCR-ABL-negative myeloproliferative disorders : Final result of a phase 2 study von JABBOUR, Elias, KANTARJIAN, Hagop, VERSTOVSEK, Srdan, CORTES, Jorge, THOMAS, Deborah, GARCIA-MANERO, Guillermo, FERRAJOLI, Alessandra, FADERL, Stefan, RICHIE, Mary Ann, BERAN, Miloslav, GILES, Francis

Volltext

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study von Jabbour, Elias, Kantarjian, Hagop, Cortes, Jorge, Thomas, Deborah, Garcia-Manero, Guillermo, Ferrajoli, Alessandra, Faderl, Stefan, Richie, Mary Ann, Beran, Miloslav, Giles, Francis, Verstovsek, Srdan

Volltext

Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia von Badar, Talha, Handisides, Damian R., Benito, Juliana M., Richie, Mary Ann, Borthakur, Gautam, Jabbour, Elias, Harutyunyan, Karine, Konoplev, Sergej, Faderl, Stefan, Kroll, Stew, Andreeff, Michael, Pearce, Tillman, Kantarjian, Hagop M., Cortes, Jorge E., Thomas, Deborah A., Konopleva, Marina

Volltext

Sorafenib plus 5-azacytidine (AZA) in older untreated FLT3 -ITD mutated AML von Ohanian, Maro, Garcia-Manero, Guillermo, Levis, Mark J., Jabbour, Elias, Daver, Naval Guastad, Borthakur, Gautam, Kadia, Tapan M., Brandt, Mark, Pierce, Sherry, Burger, Jan Andreas, Richie, Mary Ann, Patel, Keyur, Cortes, Jorge E., Kantarjian, Hagop M., Ravandi, Farhad

Volltext

Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study von Short, Nicholas J, Kantarjian, Hagop M., Loghavi, Sanam, Huang, Xuelin, Qiao, Wei, Borthakur, Gautam, Kadia, Tapan M., Daver, Naval G., Ohanian, Maro N., DiNardo, Courtney D., Estrov, Zeev E., Kanagal-Shamanna, Rashmi, Maiti, Abhishek, Benton, Christopher B., Bose, Prithviraj, Alvarado, Yesid, Jabbour, Elias J., Kornblau, Steven M., Pemmaraju, Naveen, Jain, Nitin, Gasior, Yvonne, Richie, Mary Ann, Pierce, Sherry A., Cortes, Jorge E., Konopleva, Marina Y., Garcia-Manero, Guillermo, Ravandi, Farhad

Volltext

Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITDmutation von Ohanian, Maro, Garcia-Manero, Guillermo, Jabbour, Elias J., Daver, Naval, Borthakur, Gautam, Kadia, Tapan M., Brandt, Mark, Pierce, Sherry, Burger, Jan, Richie, Mary Ann, Patel, Keyur, Cortes, Jorge E., Kantarjian, Hagop M., Ravandi, Farhad

Volltext

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia von Short, Nicholas J, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Borthakur, Gautam, Kadia, Tapan, Huang, Xuelin, Daver, Naval, DiNardo, Courtney D., Ferrajoli, Alessandra, Wierda, William G, Estrov, Zeev, Benton, Christopher B, Bose, Prithviraj, Alvarado, Yesid, Kornblau, Steven, Ohanian, Maro, Gaisor, Yvonne, Richie, Mary Ann, Pierce, Sherry, Jabbour, Elias J., Cortes, Jorge E., Ravandi, Farhad

Volltext

Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens von Khan, Maliha, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Borthakur, Gautam, Kadia, Tapan M., Huang, Xuelin, Daver, Naval, DiNardo, Courtney D, Ferrajoli, Alessandra, Wierda, William G., Estrov, Zeev, Benton, Christopher B., Bose, Prithviraj, Alvarado, Yesid, Kornblau, Steven M., Ohanian, Maro, Gasior, Yvonne, Richie, Mary Ann, Pierce, Sherry, Jabbour, Elias J., Cortes, Jorge E., Ravandi, Farhad

Volltext

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias von Konopleva, Marina, Handisides, Damian R, Richie, Mary Ann, Benito, Juliana M, Borthakur, Gautam, Jabbour, Elias J., Faderl, Stefan H., Cortes, Jorge E., Kroll, Stewart, Andreeff, Michael, Kantarjian, Hagop M, Thomas, Deborah A.

Volltext